O-090. Current clinical use of anti-oestrogen

O-33: Serum Anti-M

Comment on TR07-090

The result of the paper can be deduced from already known results in [ST06] and [BHR05]. 1 MainAfter publishing the paper in ECCC, it has come to my attention that the result provenin the paper, lower bounds for adaptive linearity tests, can be deduced from alreadyknown results.As stated in the paper, the lower bound for non-adaptive linearity tests was provenby Samorodnitsk...

Oestrogen and anti-oestrogen induction of specific gene expression in human breast cancer cells.

Approximately one-third of all human breast tumours is hormone-responsive, i.e. the growth of the tumour cells is stimulated by oestradiol [ 11. The metastases of such tumours are commonly treated with anti-oestrogenic drugs, e.g. Tamoxifen 121. I t is well established that anti-oestrogens compete with oestradiol for binding to the oestrogen receptor [3] and that their potency is related to the...

High affinity binding of anti-oestrogen to the chick liver nuclear oestrogen receptor.

Tamoxifen is a potent inhibitor of specific oestrogen-induced yolk protein synthesis by chicken liver. The oestradiol receptor in salt extracts of liver nuclei from oestrogen-treated chicks has a K(d) for oestradiol of 0.7+/-0.2nm. Tamoxifen and its metabolite, monohydroxytamoxifen, compete for binding to the salt-soluble nuclear receptor with K(i) values of 2.6 and 0.1nm respectively. The anti...

Interaction of the radiolabelled high-affinity anti-oestrogen [3H]H1285 with the cytoplasmic oestrogen receptor.

The high-affinity triarylethylene anti-oestrogen H1285 [4-(NN-diethylaminoethoxy)-beta-ethyl-alpha-(p-hydroxyphenyl) -4'-methoxystilbene] was tritiated to high specific radioactivity (35 Ci/mmol). Competition experiments between [3H]H1285 and H1285 or oestradiol demonstrated that both compounds would compete with [3H]H1285 for oestrogen-specific binding sites in rat uterine cytosol. [3H]H1285 h...